Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
NCT01006551Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Dec 2002
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ziprasidone in schizophrenia, schizoaffective disorder and schizophreniform disorder, sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Responder Status (CGI Improvement Score of 1 or 2 + 20% Reduction in PANSS) at 8 weeks. Started Dec 2002; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT01006551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01006551.